ZYN002

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) beat the consensus estimate for its fourth-quarter loss Monday and provided some highlights from its ongoing and upcoming trials. What Happened The company posted revenue of just $86,000 for the quarter ended Dec. 31, which was the only revenue...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced Thursday its Phase 2 trial for ZYN002 in Fragile X syndrome found sustained improvements in patients’ core behavioral symptoms. The drug was well tolerated with no serious adverse events. Why It’s Important The candidate is the most...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday's pre-market session but then sold off after the opening bell. The...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) investors may have reason for cautious optimism after the company’s recent Fragile X Syndrome treatment data. On Monday, Cantor Fitzgerald analyst Elemer Piros upgraded Zynerba to Overweight and said there is a reasonable change ZYN002 will find...

The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s positive Fragile X trial results with marked ambivalence. Investors propelled the stock 76 percent higher even as biotech and behavioral experts published critical reviews. Two analysts assigned Hold ratings, but Piper Jaffray...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) traded up as much as 82.6 percent Thursday after reporting positive top-line results for its uncontrolled phase 2 study of ZYN002 in children with Fragile X syndrome. The synthetic cannabinoid transdermal gel “successfully met its primary endpoint...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), plunged 56 percent in pre-market trading after the company announced that its transdermal synthetic cannabinoid treatment for epilepsy, ZYN002, didn’t demonstrate a statistically significant reduction in median seizure frequency. Rating...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), which specializes in transdermal synthetic cannabinoid treatments, has a 25-percent probability for success in its treatment of adult epilepsy, an analyst said Tuesday. Cantor Fitzgerald analyst Elemer Piros said there were no surprises in the Q2 results...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported Tuesday its second-quarter results along with a series of updates concerning ongoing clinical trials and when investors can expect top-line data. Zynerba was expected to release phase 2 STAR 1 trial data of its ZYN002 for the treatment of adult...

Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is about to embark upon a journey with unknown destinations, as investors brace for a trio of reads from the company in the third quarter of 2017. Focus: 3 Phase 2 Reads Of ZYN002 Cantor Fitzgerald said in a note released Monday it remains focused on...

Cantor Fitzgerald said in a note on Tuesday Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is poised to have three data readouts in the first half of 2017. Analyst Elemer Piros noted that the company reported the initiation of its FAB-C Phase II study with ZYN002 in children with Fragile X...

Benzinga recently had the chance to speak with Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) CEO Armando Anido about the impact the U.S. election will have on the company, the potential of Zynerba’s two main drug candidates and the health of Zynerba’s balance sheet. The Election's...

H.C. Wainwright & Co. believes that the current valuation of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has not taken into consideration the potential increased success rate of ZYN002 for epilepsy. Therefore, the firm believes the stock has the potential to deliver more than 60 percent upside...

GW Pharmaceuticals PLC (NASDAQ: GWPH)'s stock gained more than 17 percent Monday following the company's announcement of a second successful pivotal trial in an ongoing Phase 3 trial exploring its lead cannabinoid product, Epidiolex. GW Pharma's strong gains helped boost shares of...